One Day Advisor

Updated September 2026 In April 2018, a Goldman Sachs research report created an uncomfortable debate about the economics of modern medicine. The question was blunt: “Is curing patients a sustainable business model?” The report, titled The Genome Revolution , was discussing the emergence of gene therapy, genetically engineered cell therapy and gene editing. Its central observation was economically logical: a therapy that permanently eliminates a disease can reduce the number of people who need that therapy again. That creates an obvious difference between a curative or potentially one-time treatment and a chronic therapy that patients may take for years or decades. Goldman Sachs pointed to Gilead Sciences' hepatitis C franchise as an example. Gilead's highly effective hepatitis C therapies rapidly reduced the pool of untreated patients, causing sales to fall after the franchise reached its peak. Contemporary reporting quoted the Goldman analysts as arguing tha...